Stomach cancer is curable, but the chances depend heavily on how early it’s caught. When the cancer is still confined to the stomach, the five-year survival rate is about 78%. Once it spreads to distant organs, that number drops to roughly 8%. The gap between those two figures tells the whole story: early detection is the single biggest factor in whether stomach cancer can be beaten.
How Stage Affects Your Odds
Stomach cancer survival has improved significantly over the past few decades. The overall five-year survival rate has risen from 15% in the mid-1970s to 38% for diagnoses made between 2015 and 2021. That progress reflects better surgical techniques, newer drug combinations, and a growing understanding of the disease’s biology.
The numbers break down sharply by how far the cancer has spread at the time of diagnosis:
- Localized (still within the stomach): About 77% five-year survival. Roughly 32% of cases are caught at this stage.
- Regional (spread to nearby lymph nodes): About 37% five-year survival. Around 23% of cases fall here.
- Distant (spread to other organs): About 8% five-year survival. Unfortunately, 35% of cases aren’t diagnosed until this point.
The fact that more than a third of stomach cancers are already widespread at diagnosis is one of the biggest challenges with this disease. It also explains why the overall survival rate, combining all stages, remains lower than many other cancers.
Why Early Stomach Cancer Is Hard to Catch
Early stomach cancer rarely announces itself with dramatic symptoms. The most common complaint is upper abdominal pain, reported by about 70% of patients. But that kind of pain is easy to dismiss as indigestion or a mild ulcer. Other early signs, like feeling full after eating small amounts or general fatigue and loss of appetite, are vague enough that many people (and sometimes their doctors) don’t connect them to cancer right away.
In one study of younger patients, 80% had symptoms for six months to a year before receiving a diagnosis, and 10% waited one to two years. By the time most people are diagnosed, the cancer has already advanced. Doctors recommend pursuing further evaluation if you have persistent stomach pain that doesn’t improve with standard ulcer treatment, unexplained weight loss, or a family history of gastric cancer.
Surgery: The Main Path to a Cure
For stomach cancer that hasn’t spread to distant sites, surgery offers the best chance of a cure. The goal is to remove the tumor along with a margin of healthy tissue around it, ensuring no cancer cells are left behind. Many stomach cancers that have spread to nearby lymph nodes are still considered surgically removable, as long as they haven’t grown into major blood vessels or other vital structures.
The type of surgery depends on where the tumor sits and how large it is. If the cancer is in the lower or middle portion of the stomach, surgeons typically remove the affected section while preserving enough of the organ for digestion to continue. This is called a partial or distal gastrectomy, and it’s preferred when at least a four-to-six centimeter margin of clean tissue can be achieved above the tumor.
When the cancer involves a large portion of the upper stomach, or when the tumor type tends to spread along the stomach wall in ways that are hard to see, the entire stomach may need to be removed. A total gastrectomy sounds dramatic, and it does require significant lifestyle adjustments afterward, particularly around eating smaller, more frequent meals. But it can be the difference between a complete cure and leaving cancer behind.
Minimally Invasive Options for Very Early Cancer
A small subset of stomach cancers caught at the earliest possible stage can be treated without traditional surgery at all. A procedure called endoscopic submucosal dissection allows a gastroenterologist to remove the cancerous tissue through a scope passed down the throat, with no external incisions. To qualify, the tumor generally needs to be small (two centimeters or less), well-differentiated (meaning the cells still look relatively normal under a microscope), confined to the innermost lining of the stomach, and free of ulceration. Slightly larger or deeper tumors may still be eligible under expanded criteria, but the requirements are strict because the technique only works when the risk of lymph node involvement is very low.
Treatment for Advanced Stomach Cancer
When stomach cancer has spread beyond what surgery can remove, a cure becomes unlikely, but treatment can still extend life meaningfully. Chemotherapy remains the backbone of treatment for advanced disease. In recent years, two additional approaches have changed the landscape.
Immune checkpoint inhibitors are drugs that help your immune system recognize and attack cancer cells. In advanced stomach cancer, adding an immune checkpoint inhibitor to standard chemotherapy has been shown to extend median overall survival from about 15.7 months to 20 months in patients whose tumors have high levels of a protein called PD-L1. This benefit is specific: patients with low PD-L1 levels didn’t see the same improvement and in some cases fared worse with the added drug. That’s why tumors are now routinely tested for PD-L1 levels before this treatment is offered.
For the roughly 15 to 20% of stomach cancers that overproduce a protein called HER2, targeted therapy is added to the mix. HER2-targeted drugs block the signals that drive these particular cancer cells to grow. When combined with chemotherapy and, in the right patients, an immune checkpoint inhibitor, progression-free survival improved from about 7.3 months to nearly 11 months.
A real-world analysis from Japan found that the introduction of immune checkpoint inhibitors after 2017 improved median overall survival in advanced stomach cancer from 13.9 months to 16.9 months. Even after second-line treatment failed, patients in the newer treatment era survived a median of 4.3 months compared to 3.2 months previously. These are modest gains in absolute terms, but they represent a meaningful shift for a disease where treatment options were once very limited.
What “Curable” Really Means
In cancer medicine, “cured” typically means no detectable cancer remains after treatment and it doesn’t come back. For stomach cancer, this is a realistic outcome for many patients diagnosed at an early stage. The 78% five-year survival rate for localized disease means the majority of these patients are alive and cancer-free years later. Some will need long-term monitoring, dietary adjustments after surgery, and supplementation for nutrients like vitamin B12 that the stomach normally helps absorb, but they live full lives.
For regional disease, outcomes are more mixed. Some patients are cured through a combination of surgery and chemotherapy (often given both before and after the operation to shrink the tumor and eliminate microscopic disease). Others experience a recurrence. The 37% five-year survival rate reflects this uncertainty, but it also means more than one in three patients with regional spread do survive long-term.
For distant disease, treatment focuses on extending life and maintaining quality of life rather than achieving a cure. The 8% five-year survival rate is low, but it has more than doubled from 3% in earlier decades, and newer therapies continue to push that number upward for patients whose tumors have treatable molecular features.
The bottom line: stomach cancer is curable when caught early, and increasingly treatable even when it’s not. The challenge remains getting diagnosed before the disease has spread, which is why persistent digestive symptoms that don’t respond to standard treatment deserve a closer look.